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Recent studies demonstrate an association between antipsychotic-induced parkinsonism (AIP) and rs4606 SNP of RGS2 gene in Jewish and
African-Americans. The current study investigates the association between rs4606 and AIP or its subsymptoms (rest tremor, rigidity, and
bradykinesia) in 112 psychiatric inpatients of African-Caribbean origin. Presence of AIP, rigidity, bradykinesia, and tremor was measured by
the UPDRS. We applied x2 (or Fisher Exact) and logistic regression analyses in several models including rs4606, age, gender, dose of
antipsychotics, and anticholinergics, and two other putatively functional SNPs in DRD2 (141CIns/Del) and HTR2C (Cys23Ser) genes. In
contrast to recent literature, we ﬁnd no evidence for an association between rs4606 and AIP or any of its subsymptoms. We hypothesize that
the observed lack of association is due probably to differences in serotonin 2A-receptor afﬁnities of the antipsychotics utilized (in contrast to
the other published studies, the majority of our patients utilized typical antipsychotics). Copyright # 2009 John Wiley & Sons, Ltd.
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INTRODUCTION
Antipsychotic-induced parkinsonism (AIP) is an acute
movement disorder with three cardinal features:
rigidity, bradykinesia, and rest-tremor. Several risk
factors have been suggested to predispose to AIP such
as old age, female gender, high antipsychotic dose,
and hereditary predisposition (Al Hadithy et al., 2008;
Caligiuri et al., 1999; Hirose, 2006; Jabs et al., 2003).
Various neurotransmitter receptors may be involved
in the etiology of AIP. AIP may be caused by the
antagonistic effects of antipsychotics on nigrostriatal
dopamine D2 receptors (DRD2) (Reynolds, 2004). The
effects of DRD2 antagonism are however modulated
by serotonin 2A and 2C receptors (HTR2A and HT2C,
respectively) (Alex et al., 2005; Haleem, 2006).
Antagonism of muscarinic acetylcholine M1 and M3
receptors (CHRM1 and CHRM3, respectively) may
also lead to alleviation of AIP symptoms (Reynolds, 2004).
DRD2, HTR2A, HTR2C, CHRM1 and CHRM3
receptors are G-protein coupled receptors that utilize
G-protein molecules for intracellular signaling and
second-messenger activation. The intracellular signaling
of these receptors is regulated by proteins belonging to
the family of Regulators of G-protein Signaling (RGS),
which modulate the intrinsic GTPase activity and hence
the duration and intensity of the intracellular signaling
of these receptors (Greenbaum et al., 2007).
RGS2, a member of the RGS family, is involved in
the intracellular signaling of HTR2A (Ghavami et al.,
2004) and CHRM1 and CHRM3 (Bernstein et al.,
2004; Tovey and Willars, 2004) receptors. Polymorph-
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isms (SNPs) affecting RGS2 functionality may there-
fore predispose to AIP.
Greenbaum et al. (2007, 2008) have recently
reported an association between RGS2 gene and AIP
in Jewish, Caucasians and African-American patients
and have also shown that among the polymorphisms
studied, the rs4606 exhibits the strongest association
with AIP. The samples studied by Greenbaum et al.
included subjects that received atypical antipsychotics;
76% of the subjects in the African-American and
Caucasian sample and 41% in the Jewish sample
(Greenbaum et al., 2008, 2007, respectively).
As opposed to typical antipsychotics, all of the
atypical antipsychotics have strong HTR2A binding
afﬁnities (Nasrallah, 2008b). Since RGS2 is involved
in the intracellular signaling mediated by serotonin 2A
receptor (HTR2A), but not in the signalingmediated by
dopamine D2 receptors (DRD2) (Ghavami et al.,
2004), it is pharmacologically plausible that the
possible effects of rs4606 are expressed only in those
patients subjected to strong HTR2A antagonism.
We endeavored to test this hypothesis by examining
the association between rs4606 and AIP, rigidity, rest-
tremor, and bradykinesia in African-Caribbean inpa-




In this study we utilized data previously obtained from
predominantly African-Caribbean subjects (Negroid or
Mixed) (van Harten et al., 1996). All of the study
subjects were inpatients from Dr. Capriles Clinic
(Curac¸ao, Dutch Antilles) and had received almost all
of their psychiatric care from that hospital. The study
protocol was approved by the Curac¸ao institutional
review board and informed consent was obtained from
each patient after full explanation of the study.
Patients were included in this study regardless the
presence or absence of AIP and regardless the type or
severity of their mental illness. Inclusion criteria were:
(i) absence of organic and neurological disorders that
could causemovement disorders, (ii) a history of neuro-
leptic use for at least 3 months, and (iii) informed consent.
Clinical data
AIP, rigidity, bradykinesia, and rest-tremor were
measured with the motor examination part of the
Uniﬁed Parkinson Disease Rating Scale (UPDRS)
(Martinez-Martin et al., 1994). All of the ratings were
dichotomized in presence/absence of these symptoms.
Since rest-tremor and rigidity are typical of AIP, a
‘‘mild’’ involvement on one of these items led to AIP
case deﬁnition (van Harten et al., 1996). If no tremor or
rigidity was present, then the cut-off point for the
presence of AIP was at least one ‘‘moderate’’ or two
‘‘mild’’ scores on the other items (van Harten et al.,
1996). This more stringent criterion for items
concerning bradykinesia and postural stability was
chosen because these symptoms can also be caused by
psychiatric syndromes or sedation.
Two medical doctors assessed patients’ medical ﬁles
for qualitative and quantitative information on the
antipsychotic and anticholinergic medications used.
The dose of the antipsychotic and anticholinergic
medication was converted into chlorpromazine and
benztropine equivalents, respectively (Davis, 1976;
Moleman, 1992).
DNA genotyping
Genomic DNAwas extracted from EDTAwhole-blood
and genotyping was conducted blind to the clinical
status of the patients. Standard ﬂuorogenic 50-
exonuclease TaqMan1 assays were applied for the
determination of rs4606 (þ2971C>G; RGS2) and
141CIns/Del (rs1799732; DRD2) polymorphisms.
We have utilized the following primers and FAM/VIC
probes for rs4606 (forward and reverse primers, TTT
TAG TTT AGG ATT CAG TAA CAG TGA AGT GT
and GCATTA CAT GAG ACA ACA GTA CTG ATG
AT, respectively; NFQ probes, ACT ATG TGC AAG
GGT ATT and CTA TGT GCA ACG GTA TT) and
for 141C Ins/Del (forward and reverse primers;
AAA ACA AGG GAT GGC GGA AT and CCC
ACC AAA GGA GCT GTA CCT, respectively;
TAMRA probes CCT ACC CGT TCA GGC
CGGG and CCT ACC CGT TCC AGG CCGG).
Cys23Ser (rs6318, HTR2C) polymorphism was
determined by a restriction fragment length poly-
morphism (RFLP) protocols, as previously
described (Ebstein et al., 1997).
Statistics
x2 or, when appropriate, Fisher Exact tests were
applied for the association analyses. These analyses
were conducted twice: by genotype (C/C, C/G, or G/G)
or by G-allele carriership status (carriers vs. non-
carriers of the minor G-allele). Furthermore, step-wise
logistic regression analyses were conducted for several
models including age, gender, dose of antipsychotic,
and anticholinergic medication, as well as carriership
status of rs4606 (RGS2), rs1799732 (DRD2), and
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rs6318 (HTR2C). Student’s t-test was applied for
analysis of continuous data.
Departure from Hardy–Weinberg Equilibrium was
calculated for rs4606 and rs1799732 by the use of an
online tool (http://www.tufts.edu/mcourt01/Docu-
ments/Court%20lab%20-%20HW%20calculator.xls;
accessed 13 March 2008). p-values< 0.05 were
regarded as signiﬁcant.
RESULTS
Demographic and clinical features of the subjects
One hundred and twelve subjects (93 males and
19 females) met the inclusion criteria. Table 1 presents
basic demographic and clinical features.
Genotype distribution, Hardy–Weinberg
equilibrium (HWE), and allele-carriership
frequency
The genotype distributions and allele-carriership
frequencies are reported in Table 2. The genotype
distributions of rs4606 (RGS2) and 141CIns/Del
(DRD2) are in consistency with Hardy–Weinberg
Equilibrium (x2¼ 0.0020, p¼ 0.964 and x2¼ 0.0305,
p¼ 0.861; respectively).
Association between rs4606 and AIP, rigidity,
tremor, and bradykinesia
Table 2 represents the case/control ratios of AIP and its
subsymptoms per allele-carriership status. Genotype-
wise and allele-carriership wise analyses did not
provide evidence for an association between rs4606
and AIP or its subsymptoms even after correction
for age, daily use of antipsychotics and anticholiner-
gics, and allele-carriership status of 141CIns/Del
(DRD2) and Cys23Ser (HTR2C) polymorphisms.
Comparison of age and the use of antipsychotics,
anticholinergics, and benzodiazepines
Mean age, chlorpromazine and benztropine equiva-
lents, and the proportion of patients using antic-
holinergic medication did not differ signiﬁcantly
Table 1. Age, diagnosis (DSM-III-R), ethnicity, cocaine abuse, number, and type of antipsychotics used, daily use of antipsychotics and anticholinergics (in
mg/day chlorpromazine (cpzeq) and benztropine equivalents (bnzeq), respectively) on the day of assessment of the UPDRS, lifetime exposure to antipsychotics
(kg cpzeq) and the frequency of subjects with concomitant anticholinergics, benzodiazepines, antidepressants, antipsychotic-induced parkinsonism (AIP),
rigidity (RIG), rest-tremor (TREM), and bradykinesia (BRAD)
Total sample (112) Male (93) Female (19)
Age, years (meanSD) 48.5 13.5 47.2 13.1 55.0 13.6
Diagnosis, n (%)a — —
Schizophreniab 78 (80.4)
Affective disorder 5 (5.2)
Dementia or other 14 (14.4)
Cocaine abuse, n (%)c 18 (16.8) — —









Antipsychotics/day, mgCPZeq/day (mean SD) 687.0 744.2 702.1 681.3 613.0 1018.0
Lifetime antipsychotics usee, kgCPZeq (meanSD) 3.6 3.2 3.9 3.3 2.6 2.6
Anticholinergics/day, mgBNZeq/day (mean SD) 1.5 2.2 1.7 2.3 0.8 1.5
Subjects with concomitant anticholinergics, n (%) 46 (41.1) 41 (44.1) 5 (26.3)
Subjects with concomitant benzodiazepines, n (%) 25 (22.3) 23 (24.7) 2 (10.5)
Subjects with concomitant antidepressants, n (%) 7 (6.3) 3 (3.2) 4 (21.1)
AIP present, n (%) 37 (33.0) 30 (32.3) 7 (36.8)
RIG present, n (%) 11 (9.8) 9 (9.7) 2 (10.5)
TREM present, n (%) 18 (16.0) 16 (17.2) 2 (10.5)
BRAD present, n (%) 27 (24.1) 20 (21.5) 7 (36.8)
Data from 97 patients.
bIncludes 295.1, 295.2, 295.3, 295.4, 295.6, 296.7, 295.9.
cData from 107 patients.
dData from 100 patients.
eData from 83 patients (69 malesþ 14 females).
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between carriers and non-carriers of the G-alleles
or between subjects with and without AIP, rigi-
dity, rest-tremor, or bradykinesia (data not shown).
Furthermore, the frequency of patients using benzo-
diazepines did not differ signiﬁcantly between cases
and non-cases of bradykinesia or between carriers and
non- carriers of the G-allele of rs4606 polymorphism
(data not shown). Stratiﬁcation by gender did not alter
any of the above mentioned ﬁndings.The vast majority
(>90%) of the inpatients studied were using typical
antipsychotics (classical neuroleptics) and as shown in
Table 1, only 10 out of the 112 (8.9%) subjects did not
use an antipsychotic on the day of UPDRS assess-
ment.We have also applied 2 2 contingency tables to
evaluate the possible effects of polypharmacy (1
antipsychotic vs. 2 antipsychotics) on AIP, rigidity,
rest-tremor, or bradykinesia. We have also evaluated
the distribution of subjects with 1 or 2 antipsycho-
tics in relation toG-allele carriership. The comparisons
made did not reveal any signiﬁcant differences in the
utilization patterns (data not shown).
DISCUSSION
Greenbaum et al. (2007) have recently reported a
signiﬁcant association between rs4606 of RGS2 gene
and AIP (as measured by the Simpson Angus Scale,
SAS) in Jewish schizophrenic patients. In a replication
study, Greenbaum et al. (2008) have examined the
association between rs4606 with AIP (measured by
SAS as well) in 184 U.S. patients with schizophrenia
(115 African-American, 69 Caucasian). The results of
Greenbaum et al. (2008) support the association in the
overall sample as well as in the African-American
subsample.
The rs4606 polymorphism is a C!G SNP
(þ2971C>G) in the 30 untranslated regulatory region
of the RGS2 gene and is known to reduce RGS2mRNA
stability and expression (Semplicini et al., 2006).
Greenbaum et al. (2008) have fully sequenced RGS2 in
Jewish patients with and without AIP but could not ﬁnd
relevant SNPs other than the rs4606 and have
suggested that the association of rs4606 AIP is
biologically meaningful and is not a consequence of
linkage disequilibrium (LD) with another functional
variant.
Since LD is ethnicity-dependent and since African-
Caribbean subjects have similar ethnic roots to those of
African-Americans and native Africans (Page, 1997),
we endeavored in the current study to replicate the
ﬁndings of Greenbaum et al. (2007, 2008) in African-
Caribbean subjects from the Dutch Antilles.
The present study evaluates the association between
rs4606 and AIP, rigidity, tremor, or bradykinesia (all
measured by UPDRS) in subjects with a history of
chronic treatment with antipsychotics. The clinical part
(UPDRS and medication assessment) of the present
study was conducted before 1996 (van Harten et al.,
1996). Therefore, the majority of the inpatients were
treated with typical antipsychotics (classical neuro-
leptics). Because all of the subjects were inpatients
from the only psychiatric hospital in the Dutch Antilles
(Dr. Capriles Clinic), and because the natural
boundaries of these islands provide a well-deﬁned
catchment area, a good documentation of the
medications prescribed to the subjects was possible.
Although therapeutic compliance is often low in
patients using antipsychotics (Schorr et al., 2007), our
subjects were fully compliant inpatients.
In the present study we ﬁnd no evidence or support
for a signiﬁcant association between rs4606 and AIP or
Table 2. Genotype distribution, allele-carriership frequencies, case/control ratios of antipsychotic-induced parkinsonism (AIP), rigidity (RIG), rest tremor
(TREM), and bradykinesia (BRAD) per allele-carriership status
Genetic variation N (%) Allele-carriership, N (%) AIPþ: AIP RIGþ: RIG TREMþ: TREM BRADþ: BRAD
RGS2 rs4606
C/C 49 (43.8) G-allele non-carriers 18: 31 (36.7%) 3: 46 (6.1%) 8: 41 (16.3%) 13: 36 (26.5%)
C/G 50 (44.6) G-allele carriers N (%): 63 (56.2%) 19: 44 (30.2%) 8: 55 (12.7%) 10: 53 (15.9%) 14: 49 (22.2%)
G/G 13 (11.6)
DRD2 141CIns/Del
Ins/Ins 48 (42.9) Del-allele non-carriers 14: 34 (29.2%) 1: 47 (2.1%) 6: 42 (12.5%) 9: 39 (18.8)
Ins/Del 50 (44.6) Del-allele carriers N (%): 64 (57.1) 23: 41 (35.9%) 10: 54 (15.6%) 12: 52 (18.8%) 18: 46 (28.1%)
Del/Del 14 (12.5)
HTR2C Cys23Ser
Cys23/Cys23 49 (43.8) Ser-allele non-carriers 18: 52 (25.7%) 6: 64 (8.6%) 11: 59 (15.7%) 12: 58 (17.1%)
Cys23/Ser23 50 (44.6) Ser-allele carriers N (%): 63 (56.2) 19: 23 (45.2%) 5: 37 (11.9%) 7: 35 (16.7%) 15: 27 (35.7%)
Ser23/Ser23 13 (11.6)
Cases and controls are denoted by þ and , respectively.
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its subsymptoms, even after controlling for age,
pharmacotherapy, and 2 SNPs in DRD2 and HTR2C
genes (141CIns/Del and Cys23Ser, respectively).
Correction for the possible effects of these SNPs is
indicated in our study, because these SNPs have been
associated with AIP, rigidity, and bradykinesia in the
same African-Caribbean sample (Al Hadithy et al.,
2008).
There were no differences in age or in the utilization
patterns of antipsychotics, anticholinergics, and
benzodiazepines and the lack of association is there-
fore not likely to be caused by these potential
confounders.
Although there are other explanations possible for
the observed lack of association, a possible explanation
for the observed lack of association probably lies in the
differences between the types of the antipsychotics
utilized by our patients and those utilized by Green-
baum et al. (2007, 2008) patients.
In the replication study of Greenbaum et al. (2008),
which included 115 African-Americans and 69
Caucasians, atypical antipsychotics were prescribed
to at least 75.6% of the patients (25.0% risperidone,
27.2% olanzapine, and 23.4% clozapine) while only
24.4% of the patients were utilizing typical anti-
psychotics. The original study of Greenbaum et al.
(2007) consisted of 121 patients, of whom 40.5% were
treated with an atypical antipsychotic (risperidone in
all cases) plus a typical antipsychotic. In our study
population, more than 90% of the patients were using
typical antipsychotics only.
This ﬁnding might be of considerable importance,
since RGS2 has no effects on signaling mediated by
dopamine D2 receptors (DRD2) (Ghavami et al., 2004),
the major targets for the antipsychotic action of typical
antipsychotics. RGS2 is however involved in the
intracellular signaling mediated by serotonin 2A recep-
tor (HTR2A) (Ghavami et al., 2004). All of the atypical
antipsychotics (and particularly risperidone) have strong
HTR2A binding afﬁnities (Nasrallah, 2008a). There-
fore, it is pharmacologically plausible that the effect of
rs4606 on the biological functionality of RGS2 gene is
translated to neurological effects only in those patients
subjected to strong HTR2A antagonism.
AIP can be alleviated by antagonists of muscarinic
M1 and M3 receptors (CHRM1 and CHRM3, re-
spectively) and certain atypical antipsychotics
(particularly olanzapine and clozapine) are associated
with low AIP incidence, partially due to their strong
antimuscarinic afﬁnities (Raedler et al., 2000; Raedler
et al., 2003). Since RGS2 is directly involved in
CHRM1 and CHRM3 intracellular signaling (Bern-
stein et al., 2004; Tovey and Willars, 2004), a second
possible explanation may lie in the involvement of
enhanced functioning of CHRM1 and CHRM3 due to
the polymorphism. However, the proportion of subjects
on concomitant anticholinergics was in our sample
very similar to that of Greenbaum et al. (2007) (41.1 vs.
40.9%, respectively).
A third possible explanation may be related to
differences in LD patterns. Although such differences
cannot be excluded, our African-Caribbean subjects
are ethnically similar to African-Americans and may
hence have similar LD patterns to the African-
Americans studied by Greenbaum et al. (2008).
A limitation of our study, next to the sample size, is
that we did not correct for variation in the psycho-
pathology of the patients. However, our study sample
can be considered as homogenous, since the majority
of the patients was of Afro-Caribbean origin and had
schizophrenia. Additionally, the presence of organic
and neurological disorders that may cause movement
disorders was a stringent exclusion criterion. Since we
followed our patients for 10 years (van Harten et al.,
2006), neurological diseases such as Morbus Parkinson
would have been detected (Hausner, 1983). Further-
more, factors other than genetic polymophisms may
also cause the parkinsonian symptoms. Tremor for
example may be an essential rest-tremor or may be
induced by other drugs (e.g., antidepressants). How-
ever, antidepressants were used by only a few patients
(6.3%). In addition, such tremors are predominantly
postural and action tremors, whereas our trained rates
examined the patients for rest tremor, which is more
speciﬁcally related to antipsychotics and AIP.
Since bradykinesia might be caused by psychiatric
symptoms or sedation, we utilized a more stringent cut-
off point for case-deﬁnition (see Experimental Pro-
cedures, Clinical data). Additionally, we evaluated the
utilization of benzodiazepines in our sample and found
that the number of patients using benzodiazepines does
not differ signiﬁcantly between bradykinesia cases and
non-cases or between carriers and non- carriers of the
G-allele of rs4606 polymorphism.
In contrast to Greenbaum et al. (2007, 2008) who
measured AIP by SAS, we utilized UPDRS for the
assessment of AIP, rigidity, rest-tremor, or bradykine-
sia. Although it is not speciﬁcally developed to
measure AIP, several studies have utilized UPDRS
for AIP measurement (Hassin-Baer et al., 2001;
Jamora et al., 2007; Lera and Zirulnik, 1999; van
Harten et al., 1996; van Harten et al., 2006) and
UPDRS is far more comprehensive and balanced than
SAS, which has been criticized for overemphasizing
rigidity (6 out 10 items measure rigidity, while only 1
item measures tremor) (Loonen and van Praag, 2007).
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CONCLUSIONS
The present study does not support an association
between rs4606 and AIP or any of its subsymptoms.
Although differences in LD patterns can not be
excluded, a possible explanation lies more likely in
the type of antipsychotics utilized. Our ﬁndings do not
undermine the signiﬁcance of RGS2 as a promising
candidate gene for AIP but plausibly underline the
importance of integrating pharmacology into pharma-
cogenetics.
Future studies in larger samples of patients receiving
uniform antipsychotic and anticholinergic treatment
are warranted to support our hypothesis.
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